CD8A and neoplasm: Third, the benefits of dasatinib treatment are greater for TCR/pMHCI interactions of weak affinity and, as a result, dasatinib enhances the detection of low avidity CD8+ T-cells; this effect increases the number of CD8+ T-cells that can be detected directly ex vivo, particularly in the setting of tumor-specific and autoreactive CD8+ T-cell populations.